original ) (raw )Transglutaminase 2 in human diseases
Zsolt Sarang
BioMedicine, 2017
View PDFchevron_right
Correction: Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55
jorge mena
The Journal of Immunology, 2016
View PDFchevron_right
Tissue Transglutaminase in Marmoset Experimental Multiple Sclerosis: Discrepancy between White and Grey Matter
benjamin drukarch
PLoS ONE, 2014
View PDFchevron_right
Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis
Micha Wilhelmus
PloS one, 2018
View PDFchevron_right
Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Gabriel Pardo
Journal of neurology, 2017
View PDFchevron_right
Chapter 3 Local tissue Transglutaminase activity directs experimental Multiple Sclerosis pathology
Marcela Karpuj
2010
View PDFchevron_right
Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?
Micha Wilhelmus
Journal of neuroinflammation, 2017
View PDFchevron_right
Appearance of Tissue Transglutaminase in Astrocytes in Multiple Sclerosis Lesions: A Role in Cell Adhesion and Migration?
benjamin drukarch
Brain Pathology, 2011
View PDFchevron_right
Tissue transglutaminase: A novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases
benjamin drukarch
European Journal of Pharmacology, 2008
View PDFchevron_right
Author Correction: A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals
Anastasios Siokis
Nature Immunology, 2020
View PDFchevron_right
Multiple Sclerosis Journal
Ayse Altintas
2013
View PDFchevron_right
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Vissia Viglietta
New England Journal of Medicine, 2012
View PDFchevron_right
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Hans-peter Hartung
Therapeutic Advances in Neurological Disorders, 2021
View PDFchevron_right
Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions
Anne-marie Van Dam
Journal of Neuropathology & Experimental Neurology
View PDFchevron_right
Therapeutic options in multiple sclerosis: Five new things
J. Corboy
Neurology, 2010
View PDFchevron_right
Multiple sclerosis: following clues from cause to cure
Heather MacLean
The Lancet Neurology, 2009
View PDFchevron_right
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Robert Lisak
Multiple Sclerosis, 2000
View PDFchevron_right
Transglutaminase 2: A Novel Autoantigen in Canine Idiopathic Central Nervous System Inflammatory Diseases
Naoaki Matsuki
Journal of Veterinary Medical Science, 2012
View PDFchevron_right
Correction to: Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy
Supurna Ghosh
Neurochemical research, 2018
View PDFchevron_right
Immunological mechanisms in multiple sclerosis
NUR IRANI
Clinical and Applied Immunology Reviews, 2005
View PDFchevron_right
Glucose Homeostasis in Mice Is Transglutaminase 2 Independent
Siiri Iismaa
PLoS ONE, 2013
View PDFchevron_right
Correction to: Classical galactosemia: neuropsychological and psychosocial functioning beyond intellectual abilities
Esmee Oussoren
Orphanet Journal of Rare Diseases, 2020
View PDFchevron_right
Transglutaminase 6 antibodies in gluten neuropathy
Daniel Aeschlimann
Digestive and Liver Disease
View PDFchevron_right
Natural Approaches to Multiple Sclerosis
Chris Meletis
Alternative and Complementary Therapies, 2007
View PDFchevron_right
Correction: Copy Number Analysis of Complement C4A, C4B and C4A Silencing Mutation by Real-Time Quantitative Polymerase Chain Reaction
Mikko Seppänen
PLOS ONE, 2012
View PDFchevron_right
Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
Antonella Conte
Expert Review of Neurotherapeutics, 2006
View PDFchevron_right
Tissue transglutaminase modulates α-synuclein oligomerization
benjamin drukarch
Protein Science, 2008
View PDFchevron_right
Correction: Investigation of Susceptibility Genes Triggering Lachrymal/Salivary Gland Lesion Complications in Japanese Patients with Type 1 Autoimmune Pancreatitis
Masao Ota
PLOS ONE, 2016
View PDFchevron_right
Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis
Gabriele Musumeci
View PDFchevron_right
Correction to: Developmental delay and late onset HBSL pathology in hypomorphic Dars1M256L mice
Matthias Klugmann
Neurochemical Research
View PDFchevron_right
Correction: Comprehensive Gene Expression Analysis of Human Embryonic Stem Cells during Differentiation into Neural Cells
Sahar Kiani
PLoS ONE, 2011
View PDFchevron_right
Identification of Tissue Transglutaminase as a Novel Molecule Involved In Human CD8+ T Cell Transendothelial Migration
Bela Rex-Kiss
The Journal of Immunology, 2003
View PDFchevron_right
Pathogenesis of Multiple Sclerosis: How Much Space is Left for Autoimmunity?
Walter Fierz
Journal of Multiple Sclerosis
View PDFchevron_right
Transglutaminase 2 Contributes to Apoptosis Induction in Jurkat T Cells by Modulating Ca2+ Homeostasis via Cross-Linking RAP1GDS1
Jiann-jou Yang
PLoS ONE, 2013
View PDFchevron_right
Activation-induced cell death in T lymphocytes from multiple sclerosis patients
Jordi Río
Journal of Neuroimmunology, 2014
View PDFchevron_right